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In general, the actions of PGE 2 are mediated by a family of G protein-coupled receptors. Four E-prostanoid (EP) receptors, termed EP 1 through EP 4 , were originally identified pharmacologically and then further characterized by cloning (14, 30, 31, 37) . Transfection of recombinant receptors into host cells, such as Chinese hamster ovary or human embryonic kidney cells, has revealed that each receptor couples to a different signal transduction pathway. In these noncontractile cells, the EP 1 receptor activates G q proteins to elevate intracellular calcium (31); EP 2 and EP 4 stimulate cAMP production via G s (8, 30) ; and EP 3 inhibits cAMP formation via G i (8) . Alternatively, spliced isoforms have been identified for both EP 1 and EP 3 that may couple to various signaling pathways. Whether these same second messenger systems are coupled to their respective EP receptor subtypes in natural cells remains to be established.
Although the role of individual EP receptors in the renal vasculature is not known, expression and func-tion of EP receptor subtypes in the distal nephron have been characterized. The EP 1 receptor, detected in the collecting duct of humans (10, 28) and mice (35) , is reported to mediate PGE 2 inhibition of sodium reabsorption (19) . EP 3 is present in the thick ascending limb and collecting duct of humans (10, 28) , mice (29) , and rats (36) and also appears to inhibit salt and water reabsorption.
Recent studies of EP receptor distribution in rat renal cells other than epithelial have focused on mRNA expression in the glomerulus, more than on renal arteries and arterioles. Ribonuclease protection assays demonstrated predominant expression of EP 4 in rat glomeruli with lower levels of EP 1 and EP 3 (23) . In cell culture models, gene expression of EP 1 and EP 4 receptors is noted in rat mesangial cells (21) and podocytes (7) . Little is known about the function and cellular actions of EP receptor types in resistance vessels in general and the renal microcirculation in particular. Whether findings for glomeruli and cultured mesangial cells correlate with message, protein expression, and functional effects in the preglomerular arterioles is not known.
The purpose of the present study was to determine which EP receptors are expressed in preglomerular resistance vessels and, of these, which subtypes act to mediate vascular actions of PGE 2 . RT-PCR was used to identify the presence of receptor mRNA in both freshly isolated preglomerular microvessels and cultured preglomerular VSMC. Cell signaling via EP receptors was assessed in vitro by measuring cAMP production using radioimmunoassay and by measuring changes in cytosolic calcium concentration using the fluorescent dye fura 2. In vivo renal blood flow (RBF) studies evaluated renal vascular reactivity to PGE 2 injected into the renal artery. The contribution of the different EP receptors in renal resistance vessels was further defined by using pharmacological receptor agonists and antagonists in cell signaling and RBF experiments.
METHODS
Isolation of preglomerular resistance vessels. Renal preglomerular arterioles were isolated from kidneys of 6-wk-old male Sprague-Dawley rats from our Chapel Hill breeding colony (originally derived from Harlan, Indianapolis, IN) by use of previously established methodology (32, 40) . Approximately three rats were used for each preparation of isolated VSMC. Sterile solutions and equipment were used throughout. Briefly, the kidneys were infused with a magnetized iron oxide suspension (1% Fe 3 O 4 in phosphate-buffered saline), and the preglomerular vessels were separated from the rest of the cortex with the aid of a magnet, sequential sieving, and collagenase treatment. All animal protocols were performed in accordance with the University of North Carolina at Chapel Hill institutional guidelines (IACUC approval nos. 96-07-0 and 99-030-0).
Culture of VSMC. The method used to culture renal arteriolar VSMC has been described by our laboratory previously (32, 40) . Cells of the digested microvessels were collected after brief centrifugation and suspended in culture medium [RPMI 1640, supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 0.6 mM L-glutamine, and 10% fetal calf serum (Hyclone Laboratories, Salt Lake City, UT)]. The microvascular suspension was aliquoted into 60-mm culture dishes and incubated at 37°C in 5% CO 2 -95% air at 98% humidity. The next day, the medium was changed and thereafter every 2 or 3 days until the cells became confluent. After approximately 3 wk in primary culture, the cells were passaged by harvesting with 0.05% trypsin and subpassaged every 7-10 days thereafter. The cells were seeded at a density of 3-5 ϫ 10 3 cells/cm 2 . Monolayers were studied between passages 5 and 9.
RT-PCR of EP receptor subtypes. Total RNA was isolated from cultured preglomerular VSMC, freshly isolated preglomerular microvessels, whole kidney, and lung using RNA STAT-60 (Tel-Test) and treated with DNase (Life Technologies) to eliminate genomic DNA contamination. cDNA was synthesized by Superscript II RT (Life Technologies) with either random hexamer or oligo(dT) primers. PCR was performed by using Taq DNA polymerase (Boehringer Mannheim) on both cDNA and RNA with subtype-specific gene primers. The specificity of the primers was verified by using positive control clones for each subtype. EP 1 and EP 4 fulllength clones were gifts from Emiko Okuda Ashitaka (Kansai Medical Univ.) and William Smith (Michigan State Univ.), respectively. EP 2 and EP 3 clones were obtained by designing flanking primers, performing PCR on cDNA from lung and kidney, cloning the amplified fragments by using the pGEM-T Easy Vector System (Promega), and sequencing the ligated products. Primers for the housekeeping gene cyclophilin were used to verify the quality of the cDNA samples (15) . To ensure the removal of genomic DNA, a separate RNA sample was treated in the same way, except for the addition of RT. PCR assays were run in triplicate, and all PCR products were found to be the predicted size and directly sequenced to ensure their expected identity.
Determination of cAMP content. Freshly isolated preglomerular arterioles were prepared as described above, and cAMP generation was determined by using standard methodology. Briefly, a portion of the cell suspension was incubated with an equal volume of buffer A [(in mM) 50 HEPES, 8 MgCl 2 , IBMX, 2 ATP, 4 GTP, and 60 phosphocreatine as well as 800 g/ml creatine phosphokinase] and buffer B [(in mM) 50 HEPES, 1 EDTA, 1 dithiothreitol, and 0.25 sucrose as well as 1 mg/ml BSA] to give a final concentration of 50 g protein/ml. This mixture was incubated for 15 min at 37°C with ANG II (Sigma), PGE 2 (Cayman Chemical), isoproterenol (Sigma), or various EP receptor agonists [sulprostone (Cayman Chemical), 17-phenyl-PGE 2 (Cayman Chemical), butaprost (Bayer), misoprostol (Biomol), and M&B28767 (Rhone-Poulenc Rorer)]. In another set of experiments, fresh VSMC were pretreated with EP receptor antagonists [SC-19220 (Searle), AH-23848 (Glaxo-Wellcome), or AH-6809 (Biomol)] for 5 min before PGE 2 stimulation for 15 min. The reaction was stopped by adding TCA to produce a 6% final concentration. The samples were immediately put on ice and sonicated for 1 min. The cell lysate was extracted four times with 1 ml of water-saturated ether and evaporated. Aliquots were acetylated, and cAMP was measured by radioimmunoassay (Biomedical Technologies).
Measurement of cytosolic free calcium concentration. Cytosolic free calcium concentration ([Ca 2ϩ ] i ) was measured in cultured VSMC of preglomerular arterioles by using the calcium-sensitive dye fura 2-acetoxymethyl ester (AM) as described previously (32, 40) . Confluent VSMC grown on glass coverslips were subjected to serum-free medium 24 h before an experiment. Before the study, monolayers of VSMC were washed twice with Hanks' balanced salt solution [HBSS; (in mM) 135 NaCl, 5 KCl, 1 CaCl 2 , 1 MgCl 2 , 5 D-glucose, and 10 HEPES, pH 7.4] and incubated in the dark at room temperature with 2 M fura 2-AM for 60 min. After fura loading, the VSMC were washed three times with HBSS and allowed to stabilize for 20 min. Cells were excited alternately with light of 340-and 380-nm wavelength from dual monochrometers of a Photon Technology International dualexcitation wavelength Deltascan (model RMD) interfaced with an inverted microscope (Olympus IX-70). After passing through a barrier filter (510 nm), fluorescence was detected by a photometer. Fluorescence signal intensity was acquired, stored, and processed by a Pentium II computer and Felix software (Photon Technology International). Each preparation was tested only once, to avoid possible receptor desensitization or tachyphylaxis.
RBF studies. Experiments were performed on 5-to 6-wkold Sprague-Dawley rats derived from our Chapel Hill breeding colony by using standard methods for our laboratory (13) . Anesthesia was induced by an intraperitoneal injection of pentobarbital sodium (65 mg/kg body wt), and the animals were placed on a servo-controlled heating table that maintained body temperature at 37°C. A tracheostomy was performed to facilitate free breathing. Carotid arterial pressure was monitored via an indwelling PE-50 catheter connected to a Statham P23 Db transducer and a Hewlett-Packard oscillographic recorder interfaced to an IBM-clone Pentium II computer. Maintenance infusions of isooncotic albumin were made via a jugular vein. To measure RBF, a noncannulating electromagnetic flow probe (1.5-mm circumference, Carolina Medical) was placed around the left renal artery. A catheter inserted in a femoral artery was advanced into the abdominal aorta, and the tip was positioned at the origin of the renal artery for continuous infusion of heparinized isotonic saline (5 l/min) and intrarenal injection of vasoactive agents. Before injection of EP agonists, the rate of saline infusion was increased to 120 l/min; 60 s later a 10-l bolus of the particular agent was injected into the catheter positioned in the renal artery. In some experiments, the EP 1 blocker SC-19220 was infused into the artery at 120 l/min for 2 min before injection of the PGE 2 bolus. After completion of the surgical preparation, the animals were allowed to stabilize for 30 min before the measurements were started. The RBF and mean arterial pressure values were normalized and expressed as a percentage of baseline values, determined separately for each injection. Mean arterial pressure was constant during RBF responses to each injection. Plots of normalized RBF as a function of time were prepared by using the SigmaPlot software package (SPSS, Chicago, IL).
Statistics. Data are presented as means Ϯ SE. Data sets concerning signal transduction were analyzed by analysis of variance followed by post hoc testing according to StudentNewman-Keuls. Maximum RBF responses were analyzed by Student's t-test. P values Ͻ0.05 are considered statistically significant.
RESULTS
RT-PCR was used to evaluate gene expression of EP receptor subtypes in freshly isolated preglomerular arterioles and cultured preglomerular VSMC preparations. As is shown in Fig. 1A , signals indicating the presence of mRNA encoding EP 1 and EP 4 were detected in both fresh and cultured preparations by identity with the predicted product sizes of 415 and 318 bp, respectively. It should be noted that the primer used to identify EP 1 mRNA does not differentiate between the two known splice variants of the EP 1 receptor. PCR Fig. 1 . RT-PCR amplification of fragments or the E-prostanoid (EP) receptor subtypes. PCR was performed by using RNA isolated from freshly isolated preglomerular microvessels (f ), cultured preglomerular vascular smooth muscle cells (VSMC; c), and whole tissues (w). Product sizes were compared with those of a positive control plasmid (ϩ) containing a cloned portion of the particular receptor subtype. A: amplification fragments for both EP 1 and EP 4 are detectable. CYCLO, cyclophilin; cult, cultured. B: signals for EP 2 and EP 3 are undetectable in fresh and cultured renal VSMC, although fragments of the appropriate size are noted in tissues known to express the receptors, i.e., EP 2 in lung and EP 3 in kidney. C: although amplification fragments consistent with EP 1 -variant are found in both VSMC preparations, a band corresponding to EP 1 mRNA is absent from cultured VSMC. For A-C, samples were electrophoresed on 1.5% agarose gels and visualized with ethidium bromide. Left: size markers. cDNA quality was verified by amplifying each sample with cyclophilin primers. Data are representative of PCR reactions using 3 different sets of isolated microvessels and 3 separate batches of cultured VSMC. products were directly sequenced and found to be identical to reported cDNA sequences for EP 1 and EP 4 . Although we were able to amplify cyclophilin fragments from the same cDNA, expression of EP 2 or EP 3 message was undetectable in both fresh and cultured renal VSMC (Fig. 1B) . It is unlikely that this finding of receptor absence is due to an error in primer design because subtype-specific primers produced fragments of the predicted size using cDNA samples from positive control clones as well as from tissues known to strongly express each subtype, lung for EP 2 and kidney for EP 3 (30, 36) . The absence of bands in the RNA lanes indicates the elimination of genomic DNA contamination.
To assess the expression of the vasoconstrictor EP 1 receptor in more detail, another set of PCR primers was designed to distinguish between the EP 1 receptor and its variant, nonsignaling form. The EP 1 -variant consists of the first 951 bp of EP 1 , with an alternative sequence in place of the seventh transmembrane section containing a stop codon; the remaining sequence is common to both receptors. We designed the 5Ј primer to anneal within the first common region and the 3Ј primer to anneal to the terminal common sequence so that amplification of EP 1 -variant cDNA would produce a longer PCR fragment (730 bp) than native EP 1 (360 bp). Figure 1C shows detection of amplification fragments indicative of the presence of the EP 1 -variant in both cultured and fresh preparations, as well as in whole kidney samples. However, the presence of signal for EP 1 receptor mRNA differed in the two preparations. Whereas EP 1 expression was evident as a faint band in freshly isolated preglomerular microvessels, no signal was detected in cultured VSMC. A stronger band for EP 1 was clearly observed in cDNA samples derived from whole kidney tissue. As before, the identity of these amplification fragments was confirmed by direct sequencing.
To examine the functional coupling of EP 1 and EP 4 receptors to G i and or G s proteins in freshly isolated preglomerular microvessels, cAMP levels were measured after stimulation of EP receptors by relatively subtype-specific agonists. Baseline production of cAMP by renal microvessels of Sprague-Dawley rats was 6.8 Ϯ 2.5 pmol cAMP ⅐ 50 mg protein Ϫ1 ⅐ ml Ϫ1 ⅐ 15 min Ϫ1 , consistent with an earlier report in preglomerular VSMC isolated from Wistar-Kyoto and spontaneously hypertensive rat strains (33) . All EP receptor agonists were tested at three concentrations; results for the highest concentration (10 Ϫ5 M) are presented in Fig. 2 . Sulprostone and 17-phenyl-PGE 2 , both putative EP 1 and EP 3 agonists, had no effect on cAMP. Because the EP 1 receptor is thought to signal via inositol 1,4,5-triphosphate and [Ca 2ϩ ] i , the lack of a change in cAMP after EP 1 stimulation is not unexpected. Interpretation of results with EP 3 stimulation is difficult because this receptor subtype can act via either activating or inhibiting adenylate cyclase. Butaprost, which is predicted to stimulate the EP 2 receptor and presumably increase cAMP formation, had no effect on cAMP in our VSMC, suggesting a paucity of functional EP 2 receptor. These data confirm our RT-PCR findings of the absence of EP 2 mRNA transcripts. Addition of the nonselective EP 2-4 stimulator misoprostol enhanced cAMP production by 4.3 Ϯ 0.8 pmol cAMP ⅐ 50 mg protein Ϫ1 ⅐ ml Ϫ1 ⅐ 15 min Ϫ1 (P Ͻ 0.05), a stimulatory effect consistent with our earlier observation of EP 4 mRNA expression. The EP 3 agonist M&B28767 had no effect on cAMP. Fig. 2 . Effect of EP-receptor agonists and antagonists (10 Ϫ5 M) on cAMP production in freshly isolated preglomerular microvessels. Values are means Ϯ SE for 3 preparations in each group. Misoprostol, an agonist of EP [2] [3] [4] receptors, caused a significant increase when given alone (A; P Ͻ 0.05) or when coadministered with isoproterenol (B; P Ͻ 0.05). Other EP-receptor agonists were ineffective. C: both EP 4 antagonist AH-23848 (P Ͻ 0.02) and EP 1 antagonist AH-6809 (P Ͻ 0.03) decreased cAMP production in a dose-dependent manner.
In another set of experiments on the renal microvessels, cAMP production was initially stimulated by isoproterenol in an attempt to unmask any possible inhibition mediated by EP 3 receptors. Isoproterenol elevated cAMP levels to 20.1 Ϯ 1.8 pmol cAMP ⅐ 50 mg protein Ϫ1 ⅐ ml Ϫ1 ⅐ 15 min Ϫ1 (P Ͻ 0.01). Coadministration of misoprostol further stimulated cAMP production by 8.5 Ϯ 2.8 pmol cAMP ⅐ 50 mg protein Ϫ1 ⅐ ml Ϫ1 ⅐ 15 min
Ϫ1
(P Ͻ 0.05), whereas M&B28767 had no effect (Fig. 2B) . These results are consistent with the notion that there is no EP 3 receptor coupling to G i proteins in our VSMC.
To evaluate the effect of available subtype-specific antagonists on PGE 2 -induced increases in cAMP, cells were pretreated with blockers for 5 min before PGE 2 stimulation. As is shown in Fig. 2C , PGE 2 alone produced 23.9 Ϯ 1.2 pmol cAMP ⅐ 50 mg protein Ϫ1 ⅐ ml Ϫ1 ⅐ 15 min Ϫ1 (P Ͻ 0.001). The EP 4 antagonist AH-23848 dose dependently inhibited the ability of PGE 2 to stimulate cAMP production. The highest AH-23848 dose tested reduced cAMP formation by 9.2 Ϯ 1.1 pmol cAMP ⅐ 50 mg protein Ϫ1 ⅐ ml Ϫ1 ⅐ 15 min Ϫ1 (P Ͻ 0.02). The EP 1 antagonists were predicted to have no effect on PGE 2 -induced cAMP production due to presumed coupling to G q proteins. Although this was clearly the case for SC-19220, AH-6809 (10 Ϫ5 M) attenuated PGE 2 -induced cAMP levels by 7.1 Ϯ 2.9 pmol cAMP⅐50 mg protein Ϫ1 ⅐ml Ϫ1 ⅐15 min Ϫ1 (P Ͻ 0.03), suggesting AH-6809 may not be as specific for EP 1 as SC-19220.
A separate series of experiments evaluated the influence of EP receptor activation on another second messenger system, [Ca 2ϩ ] i , in cultured preglomerular VSMC. Pharmacological agents were initially administered alone to test for possible effects on baseline values. Subsequently, ANG II was added to determine the effect of these EP agents on vasoconstrictor-mediated calcium signaling. In an earlier study, we found that PGE 2 itself has no effect on basal or unstimulated [Ca 2ϩ ] i (32 (Fig. 3B) , as would be expected with the lack of expression of EP 1 mRNA in cultured VSMC. Butaprost and M&B28767 were also without effect on calcium signaling (data not shown). These calcium data confirm the absence of EP 2 and EP 3 receptors in renal VSMC. Without EP 2 and EP 3 present, it is reasonable to conclude that misoprostol acts through the EP 4 receptor to antagonize the actions of ANG II.
In other studies we assessed the effect of EP-receptor antagonists on ANG II-induced calcium responses. ] i nor ANG II-induced calcium signaling, findings that are consistent with the lack of PCR evidence for EP 1 in cultured preglomerular VSMC.
To verify the functional expression of EP receptor subtypes in renal resistance arterioles in vivo, we examined vascular reactivity by measuring changes in RBF after administration of PGE 2 and subtype-specific agents into the renal artery. Basal values for RBF and mean arterial pressure averaged 5.8 Ϯ 0.6 ml/min and 112 Ϯ 5 mmHg (n ϭ 15), respectively. A bolus of the EP 1 -receptor agonist sulprostone (200 ng) caused transient renal vasoconstriction, reducing RBF to 91.9 Ϯ 1.2% of control flow (P Ͻ 0.001) (Fig. 5A) , without affecting systemic arterial pressure. In contrast, misoprostol (200 ng) elicited a longer lasting increase in RBF to 106 Ϯ 0.8% of control flow (P Ͻ 0.001), indicating renal vasodilation in the absence of a change in arterial pressure (Fig. 5B) . To determine whether the EP 1 subtype expressed in fresh renal preglomerular VSMC is functional in vivo, rats were challenged with PGE 2 . Bolus injection of PGE 2 (200 ng) into the renal artery produced a biphasic response, characterized by immediate, short-lived constriction followed by a more sustained phase of dilation (Fig. 5C ). During the immediate transient constriction, RBF fell to 85.3 Ϯ 4.2% of control (P Ͻ 0.02), followed by a longer lasting dilatory phase in which RBF rose to a peak of 110.8 Ϯ 0.9% of baseline (P Ͻ 0.001). The constrictor period of ϳ15 s, contrasted with the prolonged dilatory phase, returned to control levels after Ͼ5 min. It is noteworthy that the initial constrictor response was completely abolished by 2-min pretreatment with the EP 1 blocker SC-19220. Selectivity was indicated by the lack of change in the sustained, elevated phase during SC-19220 administration.
DISCUSSION
We present new evidence that preglomerular resistance vessels of the rat kidney express two of the four known EP receptors, with EP 1 causing transient vasoconstriction and EP 4 eliciting long-lasting vasodilation. As PGE 2 produces net vasodilation, EP 4 is the functionally predominant receptor. Detection of the EP 4 receptor provides a mechanism for the long-standing observation that prostaglandins can effectively buffer the actions of vasoconstrictors in the renal microvasculature and thereby protect kidney function (11, 25) . EP 1 receptor expression is evident pharmacologically at the whole kidney level in vivo, and message is localized by RT-PCR to the preglomerular resistance vessels. Also present in freshly isolated microvessels is mRNA encoding a nonsignaling isoform, termed the EP 1 -variant. Interestingly, EP 1 receptors are absent in cell culture, whereas the EP 1 -variant and EP 4 receptors are retained. These observations provide a cellular 
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explanation for previous observations of PGE 2 -induced renal vasodilation as well as highlight the complexities of prostaglandin signaling in a critical vascular bed. In previous studies, PGE 2 receptors have been identified in preglomerular vessels by radioligand binding, and PGE 2 produces an increase in cAMP in freshly isolated VSMC, suggesting a dominance of vasodilator EP receptors coupled to G s proteins (33) . The present study identified a biphasic RBF response to injection of PGE 2 into the renal artery: an initial, transient vasoconstriction, followed by a much more pronounced, sustained vasodilation. On the basis of earlier work in nonvascular cell types and transfection studies in host cells, one might predict that vasodilatory signals are transduced by either EP 2 or EP 4 receptors, both of which are thought to stimulate adenylate cyclase.
Along these lines, our studies of second messenger signal transduction indicate the presence of EP 4 and absence of EP 2 receptors in preglomerular vessels. The EP 2 agonist butaprost had no effect on basal cAMP levels, baseline [Ca 2ϩ ] i , or ANG II-induced calcium signaling. On the other hand, the EP 2,3,4 agonist misoprostol significantly increased cAMP, both from baseline and when previously stimulated by isoproterenol. With regard to the limited specificity of misoprostol, it is important to note that activation of an EP 3 receptor, if present, might be predicted to decrease, rather than increase, cAMP levels. In other signaling experiments, misoprostol inhibited PGE 2 -elicited cAMP production and attenuated ANG II-induced increases in [Ca 2ϩ ] i . ANG II is known to enhance prostanoid production by preglomerular VSMC, and cAMP has been shown to counteract ANG II-elicited increases in [Ca 2ϩ ] i (32) . In this regard, we found in the present study that the EP 4 antagonist AH-23848 markedly enhanced the calcium response to ANG II. These findings are consistent with ANG II stimulation of PGE 2 production and PGE 2 action on EP 4 receptors to inhibit [Ca 2ϩ ] i via cAMP. Further support for PGE 2 -induced renal vasodilation mediated by EP 4 derives from the demonstration that misoprostol increased RBF by reducing renal arteriolar resistance in acute animal experiments. In other RBF studies we tested the efficacy of AH-23848 to block PGE 2 actions on EP 4 receptors. The preliminary results, however, were inconclusive, in large part because of the very high concentration of drug required to antagonize PGE 2 binding to EP 4 receptors (inhibition constant difference of 10,000-fold) (8) and limited availability of the compound. One can speculate at this juncture that the weak affinity of AH-23848 has less of an influence in vitro because of the drug's longer access time in isolated microvessels and VSMC. Nevertheless, our RT-PCR experiments confirm the predominance of EP 4 in PGE 2 -induced vasodilation by indicating the presence of RNA for EP 4 and the absence of message for EP 2 in both fresh and cultured preglomerular preparations. Taken together, these comprehensive data extend to resistance arterioles the suggestive pharmacological evidence of a dilator effect of EP 4 in isolated large vessels of other vascular beds (4, 27).
The presence and functional expression of EP 4 in rat arterioles elucidate the mechanisms underlying the well-known vasodilatory actions of PGE 2 . In the renal microcirculation, it has been clear for many years that PGE 2 can oppose constriction in preglomerular vessels (6, 11, 22, 25) . The activation of EP 4 by PGE 2 is crucial to maintain RBF when vasoconstrictor systems are active as, for example, during extracellular fluid volume contraction and in disease states. In regard to experimental models, previous investigations have established that an imbalance between vasodilatory and vasoconstrictor systems may contribute to the development of hypertension. In young spontaneously hypertensive rats, the dysfunction appears to arise in the interaction between a vasodilatory prostaglandin receptor and the G s protein that activates adenylate cyclase (32) . On the basis of the present results, it is reasonable to predict that this defect lies in the coupling of the EP 4 receptor to G s proteins and the cAMP pathway.
The expression of vasoconstrictor EP 1 receptors was unexpected in view of the noted predominant vasodilatory actions of PGE 2 . Nevertheless, message for this subtype has been reported in isolated glomeruli (23) and cultured mesangial cells (21) . Our RBF studies establish functional expression of the vasoconstrictor EP 1 subtype in the microcirculation in vivo. The immediate transient decrease in RBF caused by PGE 2 injection into the renal artery is fully abolished by the EP 1 antagonist SC-19220 while having little, if any, effect on the more pronounced, sustained vasodilation. Moreover, the EP 1,3 agonist sulprostone elicits renal vasoconstriction in our Sprague-Dawley rats. The fact that sulprostone does not alter cAMP in our VSMC preparation supports the notion that its actions are mediated by EP 1 , rather than EP 3 , in vivo. Interestingly, previous studies of the effect of PGE 2 on RBF in our laboratory demonstrated a vasodilator effect only, suggesting there may be strain differences in EP receptor subtype expression (12) .
Of particular interest are the changes in EP 1 expression in renal VSMC maintained in cell culture. Sulprostone as well as the EP 1 antagonists AH-6809 and SC-19220 had no effect on the putative EP 1 signaling pathway, cytosolic calcium, in cultured VSMC. This loss of expression during primary cell culture is most clearly evidenced by the detection of EP 1 message in freshly isolated cells and its absence in cultured cells. A similar loss of EP receptors in culture has been reported in rabbit cortical collecting tubule cells, evidenced by a decrease in PGE 2 binding and a loss of inhibition of cAMP formation (34) . The altered distribution of EP receptor expression in cultured VSMC may impact future studies of prostaglandin action. Although global PGE 2 function cannot be assessed in cultured preparations, the cultured VSMC could facilitate the study of EP 4 actions without confounding interactions with EP 1 signaling.
The overall modulatory influence of PGE 2 -induced vasoconstriction via EP receptors is not clear. Audoly and colleagues (3) found that, compared with male wild-type control animals, systemic administration of PGE 2 lowered arterial pressure less in mice in which the coding sequence common to EP 1 and EP 1 -variant receptors was disrupted by gene targeting. Thus the enhanced depressor response in wild-type mice presumably reflects an unexpected contribution of EP 1 receptors to apparent vasodilation, although cardiac effects cannot be excluded. Our RBF data clearly demonstrate that the EP 1 receptor mediates vasoconstriction in the renal vasculature of Sprague-Dawley rats. This divergence in EP 1 function may be explained by heterogeneous effects of EP receptor activation in various vascular beds or species differences in receptor signaling. Nevertheless, it is important to appreciate that renal vasoconstriction mediated by EP 1 is transient and plays a weaker role compared with that of the prolonged vasodilation mediated by EP 4 . Perhaps the expression of this vasoconstrictor receptor provides a means of further modulating the prostaglandin effect in the microcirculation. It is also possible that EP 1 is expressed preferentially in a subpopulation of minority nephrons with EP 4 as the predominant receptor in the more numerous population of cortical nephrons. Such a model is consistent with a previous study demonstrating solely vasoconstrictive effects of PGE 2 in the juxtamedullary nephron preparation (20) .
The only other study to differentiate between EP 1 and EP 1 -variant expression is the original work in which the EP 1 receptor variant was cloned (31). Our results document for the first time mRNA expression for the EP 1 -variant in both cultured and freshly isolated preglomerular preparations. The EP 1 -variant receptor displays the same ligand binding specificity as EP 1 but lacks the COOH-terminal signaling domain (31) . Thus the function, or lack thereof, of this subtype is difficult to establish because the portion of the receptor that couples to the G protein is truncated, and the receptor does not appear to generate signals along traditional transduction pathways. One can speculate that the expression of EP 1 -variant protein at the cell surface is regulated to finely tune the response to PGE 2 . This variant receptor may serve as a type of clearance receptor, removing excess PGE 2 from the circulation and guarding against the sudden onset of dangerously low blood pressure. It may bind PGE 2 and release it slowly to VSMC in a manner similar to that postulated for the similarly truncated form of the atrial natriuretic peptide receptor (24) . Also, the possibility that the EP 1 -variant couples to an alternative signaling pathway, such as growth regulation or metabolism, cannot be ruled out.
Species comparisons of EP renal vascular expression are complicated by conflicting results. Although ribonuclease protection assays detect primarily transcripts for EP 4 with lower levels of EP 1 and EP 3 in freshly isolated rat glomerular tissue (23) , cultured mesangial cells are reported to express EP 1 and EP 4 (21) . In mice, only EP 2 transcripts are detected in glomeruli (35) . Similarly, in situ hybridization experiments using human tissue support solely EP 4 expression (10), whereas immunohistochemistry studies detect both EP 3 and EP 4 in human glomeruli (28) . The latter study examined expression in the preglomerular vasculature, and reactivity for EP 1-3, but not EP 4 , was reported (28) . It is possible that the differences in arteriolar expression may also reflect species variation. Nevertheless, it should be emphasized that our findings concerning EP receptors in rat preglomerular VSMC are based on multiple techniques examining gene expression, cellular signaling ability, and in vivo responses, in contrast to a human study that is confined to antibody recognition of protein.
Our comprehensive findings in the preglomerular vasculature extend the several studies that have examined EP receptor expression in cultured rat glomerular mesangial cells to physiological control of renal vascular resistance and glomerular hemodynamics. Measurements of changes in cross-sectional area suggested both constrictor and dilatory actions of PGE 2 in cultured mesangial cells (26) . Furthermore, PGE 2 has been shown to evoke an increase in cytosolic calcium that can be blocked by EP 1 antagonists. The receptor subtype responsible for the increase in cAMP was not identified. In addition, mRNA message for both EP 1 and EP 4 was detected by Northern blotting in cultured rat mesangial cells (21) . A comparison of results provide evidence for phenotypic differences between cultured cells derived from preglomerular resistance arterioles and glomeruli on the basis of EP 1 receptor expression. It is not clear whether mesangial cells express the EP 1 -variant because the riboprobe used was nonselective.
Of particular interest is the potential therapeutic utility of EP subtype-specific drugs. Nonsteroidal antiinflammatory drugs, which inhibit the cyclooxygenase enzyme that produces PGE 2 , are presently among the most widely prescribed drugs. In volume-compromised conditions, administration of nonsteroidal anti-inflammatory drugs can severely reduce RBF and lead to reversible acute renal failure (39) . These undesirable side effects arise from inhibiting renal PGE 2 production and actions, which lead to tubular as well as vascular disturbances. With the high probability that EP 4 tranduces the protective vasodilator signal in the renal microcirculation, it is tempting to speculate about the development of EP receptor-specific agents that would be more selective for desired vascular effects and free of the undesirable side effects of present medications. Therapeutic drugs specific to EP receptors may allow better treatment of conditions of extracellular fluid volume contraction and hyperdynamic vasoconstrictor status in pathophysiological conditions.
In summary, the present study provides important new information about gene expression and functional characterization of EP 1 and EP 4 receptors localized to preglomerular resistance arterioles of Sprague-Dawley rats. In contrast, message for EP 2 and EP 3 was absent and no functional effect of these receptor subtypes was observed. Preglomerular VSMC express an EP 1 -variant receptor that does not appear to possess any cAMP or cytosolic calcium signaling capable of affecting RBF.
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In vivo RBF studies indicate that the EP 4 receptor is the primary receptor mediating sustained renal vasodilation produced by PGE 2 , whereas the EP 1 receptor can produce transient vasoconstriction. We conclude that the EP 4 receptor is responsible for PGE 2 -induced vasodilation in the rat kidney, signaling through G s proteins and the cAMP pathway to reduce [Ca 2ϩ ] i when stimulated by a vasoconstrictor such as ANG II.
